Imatinib Al (Imatinib)

Imatinib inhibits the ATP‑binding sites of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases. By blocking these enzymes, it prevents downstream phosphorylation events that are essential for cancer cell proliferation, survival, and angiogenesis, leading to apoptosis of the malignant cells that depend on these signaling pathways.

The prescribed dose of Imatinib Al is individualized by the treating physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and any concomitant medications. Dosage adjustments may be required for organ impairment or drug‑interaction concerns, and the prescriber sets the exact regimen.

Safety data for Imatinib in pregnancy and lactation are limited. The drug may pose risks to the fetus or nursing infant, so it should only be used if the potential benefit justifies the potential harm. Women of child‑bearing potential should discuss contraception and pregnancy planning with their healthcare provider.

To request Imatinib Al, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Imatinib was the first BCR‑ABL tyrosine‑kinase inhibitor approved for CML and remains a standard first‑line option. Newer TKIs such as dasatinib and nilotinib offer higher potency and may be chosen for patients with resistance or intolerance to imatinib, but they can have different side‑effect profiles and cost considerations.

Imatinib Al tablets should be stored at ambient temperature below 25 °C. Keep them in the original blister or container, protect from moisture and direct sunlight, and ensure the packaging remains tightly closed until use to maintain product stability.

Imatinib Al is taken orally, usually with a glass of water. It can be swallowed with or without food, although a consistent approach (with or without meals) is recommended to maintain stable absorption. Patients should follow the dosing schedule prescribed by their clinician.

Serious adverse events include hepatotoxicity, severe neutropenia or thrombocytopenia, cardiac failure, pulmonary arterial hypertension, and rare severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for liver function, blood counts, cardiac status, and any unusual skin or respiratory symptoms.

Imatinib Al is contraindicated in individuals with known hypersensitivity to imatinib or any of its excipients. Caution is also advised for patients with severe hepatic impairment, uncontrolled cardiac disease, or those taking strong CYP3A4 inhibitors that cannot be discontinued. The prescriber should evaluate each patient’s medical history before initiating therapy.